NCT00287729View on ClinicalTrials.gov

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

PHASE3CompletedINTERVENTIONAL
Enrollment

344

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Pirfenidone

2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.

DRUG

Placebo

Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.

Trial Locations (1)

94005

InterMune, Inc., Brisbane

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY